These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19740394)

  • 21. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.
    Berginc K; Trontelj J; Kristl A
    Drug Metab Pharmacokinet; 2010; 25(3):307-13. PubMed ID: 20610890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
    J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
    Lee LS; Pham P; Flexner C
    Ann Acad Med Singap; 2012 Dec; 41(12):559-62. PubMed ID: 23303112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters.
    Tron C; Allard M; Petitcollin A; Ferrand-Sorre MJ; Verdier MC; Querzerho-Raguideau J; Blanchet B; Le Priol J; Roussel M; Deugnier Y; Bellissant E; Lemaitre F
    Fundam Clin Pharmacol; 2019 Feb; 33(1):113-121. PubMed ID: 30203853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.
    Janneh O; Owen A; Chandler B; Hartkoorn RC; Hart CA; Bray PG; Ward SA; Back DJ; Khoo SH
    AIDS; 2005 Dec; 19(18):2097-102. PubMed ID: 16284458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium.
    Koeplinger KA; Raub TJ; Padbury GE; Zhao Z
    J Pharm Biomed Anal; 1999 Mar; 19(3-4):399-411. PubMed ID: 10704105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
    Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
    ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.
    Pan G; Elmquist WF
    Mol Pharm; 2007; 4(3):475-83. PubMed ID: 17388607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions.
    Berginc K; Kristl A
    J Med Food; 2011; 14(1-2):135-9. PubMed ID: 21138349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of drug transporters on cellular resistance towards saquinavir and darunavir.
    König SK; Herzog M; Theile D; Zembruski N; Haefeli WE; Weiss J
    J Antimicrob Chemother; 2010 Nov; 65(11):2319-28. PubMed ID: 20817741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
    Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
    Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
    Geretti AM; Arribas JR; Lathouwers E; Foster GM; Yakoob R; Kinloch S; Hill A; van Delft Y; Moecklinghoff C
    HIV Clin Trials; 2013; 14(1):45-50. PubMed ID: 23372114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.
    Kovalevsky AY; Louis JM; Aniana A; Ghosh AK; Weber IT
    J Mol Biol; 2008 Dec; 384(1):178-92. PubMed ID: 18834890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.
    Agarwal S; Pal D; Mitra AK
    Int J Pharm; 2007 Jul; 339(1-2):139-47. PubMed ID: 17451894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.
    Chandler B; Detsika M; Owen A; Evans S; Hartkoorn RC; Cane PA; Back DJ; Khoo SH
    Antivir Ther; 2007; 12(5):831-4. PubMed ID: 17713167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
    Coffinier C; Hudon SE; Lee R; Farber EA; Nobumori C; Miner JH; Andres DA; Spielmann HP; Hrycyna CA; Fong LG; Young SG
    J Biol Chem; 2008 Apr; 283(15):9797-804. PubMed ID: 18230615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).
    Kigen G; Edwards G
    BMC Pharmacol Toxicol; 2016 Aug; 17(1):37. PubMed ID: 27522191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.